Strategic decisions on assets are typically made in silos over months to years. We change that. AssetOS is a reasoning and synthesis software platform optimising your asset decisions as new evidence lands.
Indication strategy
Where should we develop this asset?
Indications ranked against the mechanism and disease evidence.
Feasibility & safety
Can we achieve the required exposure safely?
Selectivity, exposure and safety constraints mapped against the required drug profile.
Development plan
What must we prove next?
Experiments and development gates ordered around the key uncertainties.
Clinical & regulatory strategy
Which clinical and regulatory path fits this asset?
Clinical endpoints, regulatory routes and the evidence each path requires.
Competition & market
Where can this asset compete?
Competitors, differentiation requirements and market scenarios with their assumptions.
IP & FTO screening
Which patent claims could constrain development?
Potential blocking claims identified for counsel's review.
Partnering & licensing
Who could develop or license this asset?
Potential partners and licensing routes matched to the asset's stage and evidence.
Go/no-go
Should we fund the next stage?
The case for advancing, unresolved risks and findings that could change the decision.
Indication strategy
Feasibility & safetyExposure unresolved
Development planUpdate proposed
Clinical & regulatory strategyReview required
Competition & market
IP & FTO screening
Partnering & licensing
Go/no-goFurther studies required
Off-target panel available. Isoform selectivity and cellular engagement remain unresolved.
Resolve isoform selectivity and confirm cellular target engagement.
Solubility has been measured. A local formulation still needs to be developed.
Develop the formulation before measuring tissue and plasma exposure.
Oral PK is characterised. Exposure after local dosing is unmeasured.
After local formulation
Use the local formulation to characterise exposure before selecting doses for efficacy and tolerability studies.
After engagement & PK
Test efficacy at selected doses after target engagement and exposure are characterised.
After exposure assessment
Assess local and systemic tolerability at characterised exposure.
Connect development planning, regulatory strategy, IP and partnering decisions. Keep the plan current as new evidence changes the asset’s risks and opportunities.
Keep the development plan current.
AssetOS tracks new findings, flags changes in risk and proposes updates to the development plan.
Bring relevant evidence together.
Draw on scientific literature, trial results, regulatory reviews, patents and company disclosures.
See the rationale behind each recommendation.
See how evidence is weighed, where uncertainty remains and what would change the recommendation.
Trace each conclusion to its source.
Follow citations to the original records and see the evidence cutoff used for the assessment.
Under every plan sit our causal disease models. Each conclusion they hand the dossier is a causal graph with a citation on every arrow.
We’ll walk through your development plan together and show you where AssetOS can help.